Low α/β ratio for prostate cancer: In response to Dr. Fowler et al. [3] (multiple letter)

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 2, 2003, Pages 595-596

  Wang, Jian Z ^a   Guerrero, M ^a   Li, X Allen ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA RADIATION; BETA RADIATION; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; HUMAN; LETTER; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOSENSITIVITY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0041381048     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00363-8     Document Type: Letter

References (25)

1. Wang J.Z., Guerrero M., Li X.A. How low is the α/β ratio for prostate cancer? Int J Radiat Oncol Biol Phys. 55:2003;194-203.
2. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 52:2002;6-13.
3. Dale R.G. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 58:1985;515-528.
4. Dale R.G. Radiobiological assessment of permanent implants using tumor repopulation factors in linear-quadratic model. Br J Radiol. 62:1989;241-244.
5. Fowler J.F. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 62:1989;679-694.
6. 103Pd. Phys Med Biol. 46:2001;2557-2569.
7. Fowler J.F. The effect of overall treatment time in radiotherapy for localized prostate carcinoma. [Editorial] Int J Radiat Oncol Biol Phys. 21:1991;1087-1098.
8. Fowler J.F. Rapid repopulation in radiotherapy A debate on mechanism . Radiother Oncol. 22:1991;156-158.
9. Haustermans K., Fowler J.F. A comment on proliferation rates in human prostate cancer. [Letter] Int J Radiat Oncol Biol Phys. 48:2000;303.
10. 125I seeds . Int J Radiat Oncol Biol Phys. 28:1994;971-978.
11. Fowler J.F., Ritter M.A. A rationale for fractionation for slowly proliferating tumors such as prostatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 32:1995;521-529.
12. King C.R., DiPetrillo T.A., Wazer A.E. Optimal radiotherapy for prostate cancer Predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models . Int J Radiat Oncol Biol Phys. 46:2000;165-172.
13. 103Pd. Int J Radiat Oncol Biol Phys. 47:2000;1165-1167.
14. Armpilia C.I., Dale R.G., Coles I.P., et al. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Radiat Oncol Biol Phys. 55:2003;378-385.
15. Pollack A., Zagars G.K., Kavadi V.S. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 74:1994;670-678.
16. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 43:1999;1095-1101.
17. Fowler J., Chappell R., Ritter M. Is α/β for prostate cancer really low? Int J Radiat Oncol Biol Phys. 50:2001;1021-1031.
18. Thames H.D., Bentzen S.M., Turresson I., et al. Fractionation parameters for human tissues and tumors. Int J Radiat Biol. 56:1989;701-710.
19. Bentzen S.M., Ruifrok A.C.C., Thames H.D. Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck Clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy . Radiother Oncol. 38:1996;89-101.
20. Bentzen S.M., Saunders M.I., Dische S. Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiother Oncol. 53:1999;219-226.
21. Kampinga H.H., Hiemstra Y.S., Konings A.W.T., et al. Correlation between slowly repairable double-strand breaks and thermal radiosensitization in the human HeLa S3 cell line. Int J Radiat Biol. 72:1997;293-301.
22. Steel G.G., Deacon J.M., Duchesne G.M., et al. The dose-rate effect in human tumor cells. Radiother Oncol. 9:1987;299-310.
23. Levegrün S., Jackson A., Zelefsky M.J., et al. Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer Pitfalls in deducing radiobiologic parameters for tumors from clinical data . Int J Radiat Oncol Biol Phys. 51:2001;1064-1080.
24. King C.R., Mayo C.S. Is the prostate α/β ratio of 1.5 from Brenner and Hall a modeling artifact? [Letter] Int J Radiat Oncol Biol Phys. 47:2000;536-538.
25. Levegrün S., Jackson A., Zelefsky M.J., et al. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol. 63:2002;11-26.